Pharma R&D Review: What Changed In 2018, What To Look Out For In 2019

After the US Food and Drug Administration (FDA)’s stated that “the clinical trial system is broken,” regulatory agencies began working to formally figure out how real-world evidence will be used in new drug submissions and for new uses of existing drugs. The business potential is huge: organizations can reduce the time and cost of bringing new drugs to market by relying on existing real-world data and new sources of unstructured data, e.g., EHRs and social media. Most importantly, this real-world data can get patient-saving drugs to market more quickly with fewer post-release adverse events.

The impact of Brexit on the life sciences industry: separating fact from fiction to prepare for the impact of a change in the relationship between the UK and EU.

Developing and bringing a new drug to market is a long, expensive, and uncertain process. It’s even more complicated when it comes to complex products such as modified-release products and biologics. Bio/pharma companies can adopt proven strategies to increase the success of a product launch: cross-functional team collaboration, risk understanding and mitigation, a dedicated team, and the right project management tools. In this webcast, experts will share insights gained from decades of experience launching new products and discuss case studies demonstrating how to reliably bring products to market quickly without sacrificing compliance.

At Natoli Scientific, we’re in the lab every day compiling thorough USP Tablet Compression Characterization data to help you identify and solve compaction problems and provide solutions.